Why Guardant Health’s latest earnings matter for investors

Guardant Health (GH) just released second quarter 2026 results, reported a wider net loss alongside higher sales, raised full year revenue guidance, and filed a broad shelf registration covering multiple types of securities.

For investors, these updates highlight three key areas to watch. First is how the higher sales and continued losses affect the company’s path toward profitability. Second is what the revised 2026 revenue outlook implies for expected business activity. Third is how the new shelf registration might influence Guardant Health’s future financing options and capital structure.

Guardant Health’s 1 day share price return of 6.92% following the earnings release sits on top of a 90 day share price return of 76.05%. The 1 year total shareholder return of 210.68% and 3 year total shareholder return of about 4x highlight how strongly sentiment has shifted toward the stock.

If Guardant Health’s recent move has you thinking about other potential opportunities in healthcare and AI, it could be a good time to scan 43 healthcare AI stocks

After a move like Guardant Health’s, it is hard to tell what is really in the driver’s seat. Are investors reacting to improving business metrics, or is sentiment running ahead of what the current valuation supports?

Most Popular Narrative: 1.5% Undervalued

Guardant Health’s last close at $168.48 sits slightly below the most widely followed fair value estimate of about $171.08, which assumes very ambitious growth and profitability shifts over the next few years.

Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility. Significant improvements in operational scale, evidenced by material reductions in cost of goods sold and sharply improving gross margins in both Shield and Reveal, are fueling operating leverage, accelerating the path toward profitability and cash flow breakeven, and enhancing long-term margin expansion as test volumes scale.

Want to see what sits behind that fair value for Guardant Health? The narrative leans on rapid revenue compounding, a sharp margin swing, and a future earnings multiple that is anything but ordinary.

Result: Fair Value of $171.08 (UNDERVALUED)

However, Guardant Health’s story can shift quickly if high R&D and Shield investment keep cash burn elevated, or if payer adoption and reimbursement decisions prove slower than expected.

Another view on Guardant Health’s valuation

The earlier fair value of $171.08 for Guardant Health relies heavily on long term forecasts. Looking at today’s pricing, the stock trades on a P/S of 19.1x, compared with 1.4x for the US Healthcare industry, 1.5x for peers, and a fair ratio of 9.6x.

That gap suggests investors are paying a substantial premium versus both the sector and where the fair ratio indicates the market could move. The key question is whether Guardant Health’s growth and margin story is strong enough, and durable enough, to keep justifying that kind of stretch multiple.

Next Steps

Guardant Health’s recent gains and mixed signals on risks and rewards may leave you with more questions than answers, which is healthy for any investment decision. Take a moment to review the data, stress test your own assumptions, then weigh 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Guardant Health?

If Guardant Health’s surge has sharpened your interest in what else might be missing from your watchlist, do not leave potential opportunities on the table.

• Target potential mispricings by scanning companies that look cheaply valued on solid fundamentals through the 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with robust yields and staying power using the 8 dividend fortresses.
• Focus on resilience by searching for companies with sturdy balance sheets and dependable metrics via the solid balance sheet and fundamentals stocks screener (49 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.